Publication:
Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)

Simple item page
dc.contributor.authorButi, Maria
dc.contributor.authorStepanova, Tatjana
dc.contributor.authorCelen, Mustafa K.
dc.contributor.authorFlisiak, Robert
dc.contributor.authorRyder, Stephen D.
dc.contributor.authorStreinu, Adrian Cercel
dc.contributor.authorFlaherty, John F.
dc.contributor.authorGaggar, Anu
dc.contributor.authorSuri, Vithika
dc.contributor.authorMo, Shuyuan
dc.contributor.authorSubramanian, Mani
dc.contributor.authorNurmukhametova, Elena
dc.contributor.authorZoulim, Fabien
dc.contributor.authorAndreone, Pietro
dc.contributor.authorMarcellin, Patrick
dc.contributor.buuauthorGürel, Selim
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentDahiliye Ana Bilim Dalı
dc.contributor.departmentGastroenteroloji Bilim Dalı
dc.contributor.researcheridHLH-8209-2023
dc.date.accessioned2023-09-21T06:23:30Z
dc.date.available2023-09-21T06:23:30Z
dc.date.issued2017-10
dc.descriptionBu çalışma, 20-24, Ekim 2017 tarihlerinde Washington[Amerika]’da düzenlenen 68. Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting Kongresi‘nde bildiri olarak sunulmuştur.
dc.description.sponsorshipAmer Assoc Study Liver Dis
dc.description.sponsorshipGilead Sciences
dc.description.sponsorshipJohnson & Johnson Johnson & Johnson USA Janssen Biotech Inc
dc.description.sponsorshipAbbVie
dc.description.sponsorshipRoche Holding
dc.description.sponsorshipAssemblypharm
dc.description.sponsorshipContravir
dc.description.sponsorshipArbutus
dc.description.sponsorshipSanofi
dc.description.sponsorshipBristol-Myers Squibb
dc.description.sponsorshipMerck & Company Schering Plough Corporation
dc.identifier.citationButi, M. vd. (2017). ''Efficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)''. Hepatology, 66(Supplement 1), Special Issue, 488A-488A.
dc.identifier.endpage488A
dc.identifier.issn0270-9139
dc.identifier.issn1527-3350
dc.identifier.issueSupplement 1, Special Issue
dc.identifier.startpage488A
dc.identifier.urihttps://aasldpubs.onlinelibrary.wiley.com/loi/15273350
dc.identifier.urihttp://hdl.handle.net/11452/33935
dc.identifier.volume66
dc.identifier.wos000412089801057
dc.indexed.wosSSCI
dc.indexed.wosCPCIS
dc.language.isoen
dc.publisherWiley
dc.relation.collaborationYurt dışı
dc.relation.collaborationYurt dışı
dc.relation.journalHepatology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectGastroenterology & hepatology
dc.subject.wosGastroenterology & hepatology
dc.titleEfficacy and safety of tenofovir alafenamide (TAF) at 96 weeks in chronic HBV (CHB) patients with risk factors for use of tenofovir disoproxil fumarate (TDF)
dc.typeMeeting Abstract
dc.wos.quartileQ1
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Dahiliye Ana Bilim Dalı/Gastroenteroloji Bilim Dalı
local.indexed.atWOS

Files

License bundle

Now showing 1 - 1 of 1
Placeholder
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

İndeksli Yayınlar / Indexed Publications